Neurogene has reached a major milestone in its development of a potential gene therapy for Rett syndrome, underscoring how Houston’s life sciences ecosystem is helping biotechnology companies grow from early-stage innovation to late-stage clinical development.
Founded in Houston, Neurogene has scaled alongside the region’s expanding network of researchers, clinicians, investors and commercialization partners. The company’s completion of dosing in the Embolden™ registrational trial of NGN-401 demonstrates the type of innovation Houston is increasingly known for as it strengthens its position as a leading life sciences hub.
The clinical-stage biotechnology company enrolled and dosed 25 participants in the trial, exceeding its original enrollment target of 20. While the statistical analysis plan specified an intent-to-treat population of up to 24 participants, Neurogene elected to enroll all eligible participants already in screening to ensure timely completion of dosing.
“We are pleased to have completed dosing in the Embolden trial of NGN-401 within our original timeline while exceeding our enrollment target, reflecting both the significant unmet need and strong demand from the Rett syndrome community,” stated Rachel McMinn, Ph.D., Founder and Chief Executive Officer of Neurogene. “This milestone brings us one step closer to delivering a potential best-in-class, one-time treatment for Rett syndrome. We are deeply grateful to the participants, their families and the investigators for their trust, partnership and ongoing support of the development of NGN-401. We look forward to sharing topline results from Embolden in the second half of 2027 and advancing NGN-401 towards a planned BLA submission.”
Read More: Eli Lilly Acquires Houston Biotech Startup CrossBridge Bio
From Houston Startup to Late-Stage Clinical Development
Neurogene’s progress reflects the broader momentum of Houston’s life sciences industry. Companies across the region increasingly have access to the research institutions, clinical expertise, investment capital and commercialization infrastructure needed to advance breakthrough therapies.
Recent investments—including Eli Lilly’s manufacturing campus at Generation Park, the continued growth developments including the Alexandria Center for Advanced Technologies, Levit Green and TMC Helix Park, and expanded biotech workforce initiatives—are strengthening Houston’s ability to support companies throughout the innovation pipeline, from discovery to manufacturing.
Neurogene’s latest milestone adds to that momentum, demonstrating how companies founded in Houston can continue to grow while advancing therapies with the potential to improve patients’ lives.
To learn more about Houston’s life sciences and biotechnology ecosystem, visit our website.